146 related articles for article (PubMed ID: 28593748)
1. Characteristics and response to treatment among Indigenous people receiving injectable diacetylmorphine or hydromorphone in a randomised controlled trial for the treatment of long-term opioid dependence.
Oviedo-Joekes E; Palis H; Guh D; Marchand K; Brissette S; Lock K; MacDonald S; Harrison S; Anis AH; Krausz M; Marsh DC; Schechter MT
Drug Alcohol Rev; 2018 Jan; 37(1):137-146. PubMed ID: 28593748
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of hydromorphone for severe opioid use disorder: findings from the SALOME randomized clinical trial.
Bansback N; Guh D; Oviedo-Joekes E; Brissette S; Harrison S; Janmohamed A; Krausz M; MacDonald S; Marsh DC; Schechter MT; Anis AH
Addiction; 2018 Jul; 113(7):1264-1273. PubMed ID: 29589873
[TBL] [Abstract][Full Text] [Related]
3. Hydromorphone Compared With Diacetylmorphine for Long-term Opioid Dependence: A Randomized Clinical Trial.
Oviedo-Joekes E; Guh D; Brissette S; Marchand K; MacDonald S; Lock K; Harrison S; Janmohamed A; Anis AH; Krausz M; Marsh DC; Schechter MT
JAMA Psychiatry; 2016 May; 73(5):447-55. PubMed ID: 27049826
[TBL] [Abstract][Full Text] [Related]
4. Men's and women's response to treatment and perceptions of outcomes in a randomized controlled trial of injectable opioid assisted treatment for severe opioid use disorder.
Palis H; Marchand K; Guh D; Brissette S; Lock K; MacDonald S; Harrison S; Anis AH; Krausz M; Marsh DC; Schechter MT; Oviedo-Joekes E
Subst Abuse Treat Prev Policy; 2017 May; 12(1):25. PubMed ID: 28526048
[TBL] [Abstract][Full Text] [Related]
5. Double-blind injectable hydromorphone versus diacetylmorphine for the treatment of opioid dependence: a pilot study.
Oviedo-Joekes E; Guh D; Brissette S; Marsh DC; Nosyk B; Krausz M; Anis A; Schechter MT
J Subst Abuse Treat; 2010 Jun; 38(4):408-11. PubMed ID: 20359843
[TBL] [Abstract][Full Text] [Related]
6. Safety profile of injectable hydromorphone and diacetylmorphine for long-term severe opioid use disorder.
Oviedo-Joekes E; Brissette S; MacDonald S; Guh D; Marchand K; Jutha S; Harrison S; Janmohamed A; Zhang DZ; Anis AH; Krausz M; Marsh DC; Schechter MT
Drug Alcohol Depend; 2017 Jul; 176():55-62. PubMed ID: 28521199
[TBL] [Abstract][Full Text] [Related]
7. Predictors of non-use of illicit heroin in opioid injection maintenance treatment of long-term heroin dependence.
Oviedo-Joekes E; Sordo L; Guh D; Marsh DC; Lock K; Brissette S; Anis AH; Schechter MT
Addict Behav; 2015 Feb; 41():81-6. PubMed ID: 25452049
[TBL] [Abstract][Full Text] [Related]
8. Client satisfaction among participants in a randomized trial comparing oral methadone and injectable diacetylmorphine for long-term opioid-dependency.
Marchand KI; Oviedo-Joekes E; Guh D; Brissette S; Marsh DC; Schechter MT
BMC Health Serv Res; 2011 Jul; 11():174. PubMed ID: 21791093
[TBL] [Abstract][Full Text] [Related]
9. The SALOME study: recruitment experiences in a clinical trial offering injectable diacetylmorphine and hydromorphone for opioid dependency.
Oviedo-Joekes E; Marchand K; Lock K; MacDonald S; Guh D; Schechter MT
Subst Abuse Treat Prev Policy; 2015 Jan; 10():3. PubMed ID: 25619263
[TBL] [Abstract][Full Text] [Related]
10. Employment and paid work among participants in a randomized controlled trial comparing diacetylmorphine and hydromorphone.
Nikoo M; Vogel M; Choi F; Song MJ; Burghardt J; Zafari Z; Tabi K; Frank A; Barbic S; Schütz C; Jang K; Krausz M
Int J Drug Policy; 2018 Jul; 57():18-24. PubMed ID: 29655955
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal patterns of cocaine use among patients receiving injectable hydromorphone or diacetylmorphine for the treatment of opioid use disorder: A growth curve modeling approach.
Palis H; Guh D; MacDonald S; Harrison S; Brissette S; Marsh DC; Schechter MT; Oviedo-Joekes E
Drug Alcohol Depend; 2021 Jan; 218():108333. PubMed ID: 33268225
[TBL] [Abstract][Full Text] [Related]
12. Potency ratio of hydromorphone and diacetylmorphine in substitution treatment for long-term opioid dependency.
Oviedo-Joekes E; Marsh DC; Guh D; Brissette S; Schechter MT
J Opioid Manag; 2011; 7(5):371-6. PubMed ID: 22165036
[TBL] [Abstract][Full Text] [Related]
13. Treatment with injectable hydromorphone: Comparing retention in double blind and open label treatment periods.
Oviedo-Joekes E; Palis H; Guh D; Marchand K; Brissette S; Harrison S; MacDonald S; Lock K; Anis AH; Marsh DC; Schechter MT
J Subst Abuse Treat; 2019 Jun; 101():50-54. PubMed ID: 31174713
[TBL] [Abstract][Full Text] [Related]
14. Diacetylmorphine versus methadone for the treatment of opioid addiction.
Oviedo-Joekes E; Brissette S; Marsh DC; Lauzon P; Guh D; Anis A; Schechter MT
N Engl J Med; 2009 Aug; 361(8):777-86. PubMed ID: 19692689
[TBL] [Abstract][Full Text] [Related]
15. Expanding access to diacetylmorphine and hydromorphone for people who use opioids in Canada.
Maghsoudi N; Bowles J; Werb D
Can J Public Health; 2020 Aug; 111(4):606-609. PubMed ID: 32221867
[TBL] [Abstract][Full Text] [Related]
16. Characteristics and response to treatment among Aboriginal people receiving heroin-assisted treatment.
Oviedo-Joekes E; Guh D; Marsh DC; Brissette S; Nosyk B; Krausz M; Anis A; Christian WM; Spittal P; Schechter MT
Can J Public Health; 2010; 101(3):210-2. PubMed ID: 20737811
[TBL] [Abstract][Full Text] [Related]
17. Heroin assisted treatment for key health outcomes in people with chronic heroin addictions: A context-focused systematic review.
McNair R; Monaghan M; Montgomery P
Drug Alcohol Depend; 2023 Jun; 247():109869. PubMed ID: 37086659
[TBL] [Abstract][Full Text] [Related]
18. The association between nicotine dependence and physical health among people receiving injectable diacetylmorphine or hydromorphone for the treatment of chronic opioid use disorder.
Palis H; Marchand K; Karamouzian M; MacDonald S; Harrison S; Guh D; Lock K; Brissette S; Anis AH; Krausz M; Marsh DC; Schechter MT; Oviedo-Joekes E
Addict Behav Rep; 2018 Jun; 7():82-89. PubMed ID: 29892701
[TBL] [Abstract][Full Text] [Related]
19. History of reported sexual or physical abuse among long-term heroin users and their response to substitution treatment.
Oviedo-Joekes E; Marchand K; Guh D; Marsh DC; Brissette S; Krausz M; Anis A; Schechter MT
Addict Behav; 2011; 36(1-2):55-60. PubMed ID: 20855171
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of Ottawa, Canada's Managed Opioid Program (MOP) where supervised injectable hydromorphone was paired with assisted housing.
Harris MT; Seliga RK; Fairbairn N; Nolan S; Walley AY; Weinstein ZM; Turnbull J
Int J Drug Policy; 2021 Dec; 98():103400. PubMed ID: 34469781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
